• A.P. Pharma Inc., of Redwood City, Calif., said it plans to initiate a Phase II study for its post-surgical pain product, APF112, in the next month. The company intends to initiate the trial for the treatment of pain in patients following repair of inguinal hernia. Its APF112 incorporates mepivacaine, a local anesthetic with analgesic properties.

• Agilent Technologies Inc., of Palo Alto, Calif., said it introduced new methods for optimizing RNAi experiments in gene silencing, combining the siRNA technology of Qiagen NV, of Venlo, the Netherlands, with Agilent's 2100 bioanalyzer. Separately, it said that Faraday Technology Corp., of Hsinchu, Taiwan, selected the Agilent 93000 SOC (system-on-a-chip) Series for ASIC (application-specific integrated circuit) and IP chip testing. Faraday chose the Agilent C200e model for its capability in analogue and digital quad-site testing, Agilent said.

• AltaRex Corp., of Edmonton, Alberta, said in its second-quarter financial results that its cash position was $400,000 as of June 30, sufficient to fund operations "into the fourth quarter of 2003." It said it was pursuing alliances and financing options to raise the cash required to continue funding operations. AltaRex is focused on foreign antibodies that modulate the immune system for the treatment of certain cancers and other diseases.

• Amgen Inc., of Thousand Oaks, Calif., said Aranesp SingleJect, which was approved in December, is commercially available. The prefilled syringe has the same label indications as Aranesp in vials, but with a lower injection volume. Aranesp received its first approval - in anemia associated with chronic renal failure, including patients on dialysis and those who are not - in September 2001. (See BioWorld Today, Sept. 19, 2001.)

• Antisoma plc, of London, said it received approval for a voluntary delisting from the Nasdaq Europe Market, effective on the close of business Sept. 10. The decision to delist stems from Nasdaq Europe's announcement that it will close by the end of November, Antisoma said. Antisoma is developing products for cancer.

• Corixa Corp., of Seattle, said the Biologics and Genetic Therapies Directorate of Health Canada accepted Corixa's new drug submission for Bexxar under a priority review. GlaxoSmithKline Inc., a division of GlaxoSmithKline plc, of London, will market the drug in Canada. The FDA approved Bexxar in June for the treatment of non-Hodgkin's lymphoma. (See BioWorld Today, July 1, 2003.)

• CytoGenix Inc., of Houston, reported that Phanuel Pursuits LLC, an international trading company in the British Virgin Islands, exercised its option for an exclusive license for the manufacture and distribution of CytoGenix's anti-herpes topical cream in the People's Republic of China. Phanuel also obtained an option for a similar arrangement for India.

• Endovasc Inc., of Montgomery, Texas, said its wholly owned subsidiary, Nutraceutical Development Corp., will issue a stock dividend to Endovasc stockholders of record on Aug. 29. Endovasc's board will issue a dividend of one share of the Series Nutraceutical Development Corp. common stock for each four shares of Endovasc common stock.

• Generex Biotechnology Corp., of Toronto, said it reported details from studies earlier this week at the 18th International Diabetes Federation Congress in Paris. The studies indicated that the company's Oralin insulin formulation has the potential to be used in place of injected insulin to treat patients with Type I and Type II diabetes. Oralin is delivered as a fine spray to the buccal cavity via the company's Rapidmist device. The formulation is absorbed through the buccal mucosal lining.

• ICN Pharmaceuticals Inc., of Costa Mesa, Calif., completed its acquisition of Ribapharm Inc. by merging a wholly owned subsidiary into Ribapharm. On Aug. 22, each outstanding share of Ribapharm common stock not owned by ICN was converted into the right to receive the same $6.25 per share in cash, without interest, that ICN paid for each share tendered in its completed tender offer for all of the outstanding Ribapharm shares that ICN did not already own.

• Large Scale Biology Corp., of Vacaville, Calif., said it expects to enter the research-grade aprotinin market during the second quarter of 2004 as a result of progress with the field production and biomanufacturing program initiated at its Owensboro, Ky., facility in April. Employing its patented Geneware technology, LSBC conducted field trials of the recombinant aprotinin and is planning industrial-scale production of its active pharmaceutical ingredient for use in research and development.

• MacroChem Corp., of Lexington, Mass., said it is expanding a double-blind Phase II trial of Topiglan, its topical cream for erectile dysfunction, into the U.S. Topiglan combines alprostadil, a vasodilator, with SEPA, MacroChem's drug absorption enhancer. Trial sites in the U.S. will follow the same protocol as an ongoing trial in the UK. MacroChem's stock (NASDAQ:MCHM) rose 23 cents Tuesday, or 25.6 percent, to close at $1.12.

• MdeChem Inc., of Houston, said its antiviral, antibacterial product, Maxheal, developed in collaboration with Omega Pharmaceuticals, of Birmingham, Ala., was accepted for testing for control of coronavirus-severe acute respiratory syndrome under a program funded by the National Institutes of Health in Bethesda, Md. Maxheal is approved for sale in Costa Rica as an antibacterial and wound-healing agent.

• Meditech Pharmaceuticals Inc., of Scottsdale, Ariz., reported that Elan Bio Dynamics Ltd., Bio-D-Tec Inc. and Meditech signed a shareholders' agreement, which gives Bio-D-Tec, an Elan/Meditech joint venture, the rights to an Elan scanner and Meditech's aflatoxin technologies. Elan Group plc, of Dublin, Ireland, developed a noninvasive spectrometric chemical detection system with applications in the anti-bioterrorism, agricultural and environmental industries. Meditech's compound was tested against the formation of aflatoxins with positive results. Bio-D-Tec is pursuing potential equity, governmental and strategic alliances to market a solution to bioterrorism.

• Noven Pharmaceuticals Inc., of Miami, is the subject of a class-action lawsuit filed by purchasers of Noven stock during the period between Oct. 29, 2001, and April 28, 2003. The complaint charges Noven and certain of its officers and directors with making false and misleading statements regarding the rationale and marketing strategies for approval of MethyPatch, permitting Noven to inflate the value of its technology to shareholders. MethyPatch is a transdermal delivery system designed for the once-daily treatment of attention deficit hyperactivity disorder.

• Novuspharma SpA, of Bresso, Italy, reported the publication of the results of a Phase II study for Pixantrone in relapsed aggressive non-Hodgkin's lymphoma. Those results demonstrated an overall response rate of 30 percent, with 17 percent of patients experiencing a complete disappearance of their tumor following Pixantrone therapy. Response to treatment averaged 11 months, with some patients still in remission 24 months following treatment. Grade 4 neutropenia was the most frequently reported side effect, observed in 13 patients. The results were published in the August 2003 issue of Haematologica, Journal of Haematology.

• Phase Bioscience Inc., of Research Triangle Park, N.C., received a Phase I Small Business Innovation Research grant for application of its core technology to enzyme carriers. The company will use the proceeds of the SBIR grant to expand its deltaPhase technology into the biocatalysis and industrial enzyme markets. The grant will be used initially for the development of carriers for glycosylation enzymes currently being evaluated by Neose Technologies Inc., of Horsham, Pa.

No Comments